Protein / target

Interleukin-3 receptor subunit alpha

Encoded byIL3RAP26951Homo sapiensSwiss-Prot

UniProt: P26951 Ensembl: ENSG00000185291 HGNC: HGNC:6012 NCBI Gene: 3563

Clinically validated

Therapeutic maturity

Approved medicines

Open Targets target-level

Small-molecule tractable

Druggability

Structure with Ligand

Research papers

Protein at a glance

Biological role

Interleukin-3 receptor

Strongest disease association

Leukemia, Myeloid, Acute

Via encoding gene IL3RA · Literature evidence · score 0.48

Therapeutic position

Established drug target

Antibodies

Research activity

Emerging research

3 papers · latest 2016

Derived from structured UniProt, Open Targets and literature data on this page.

Protein profile

UniProt 2026_02

Canonical identity and biological annotation from UniProt.

Function overview

View complete UniProt function annotation

Cell surface receptor for IL3 expressed on hematopoietic progenitor cells, monocytes and B-lymphocytes that controls the production and differentiation of hematopoietic progenitor cells into lineage-restricted cells (PubMed:10527461). Ligand stimulation rapidly induces hetrodimerization with IL3RB, phosphorylation and enzyme activity of effector proteins such as JAK2 and PI3K that play a role in signaling cell proliferation and differentiation. Activation of JAK2 leads to STAT5-mediated transcriptional program (By similarity)

Subcellular location

Cell membrane

Domains and Gene Ontology detail (9)

Gene Ontology

Cexternal side of plasma membrane
Cplasma membrane
Creceptor complex
Fcytokine binding
Fcytokine receptor activity
Finterleukin-3 receptor activity
Pcytokine-mediated signaling pathway
Pinterleukin-3-mediated signaling pathway
Ppositive regulation of cell population proliferation

378 aa · 43 kDa · 2 isoforms

Biological roles

What this protein does, drawn together from its UniProt function, Gene Ontology terms and Reactome pathways.

Cell proliferation & survivalGOImmune signallingGO

View supporting evidence

Cell proliferation & survival

·positive regulation of cell population proliferation

Immune signalling

·cytokine binding
·cytokine receptor activity
·interleukin-3 receptor activity
·cytokine-mediated signaling pathway

Concepts derived from UniProt GO Reactome — each badge above shows which sources supported that role.

Translational evidence

Open Targets 26

Why this target matters therapeutically, strongest evidence first. Disease associations are gene-level (via the gene that encodes this protein) and open into the full confidence synthesis; the development universe, tractability and safety annotations are target-level, from Open Targets.

Strongest disease associations · via encoding gene IL3RA

Gene-level evidence surfaced through the gene IL3RAthat encodes this protein — not a direct protein–disease relationship. Ranked by Forefront's causal-directness weighting, so genetically- and clinically-evidenced diseases lead over ones that merely share the literature.

Leukemia, Myeloid, Acute

0.62Moderately supported

Clinical evidence dominant · Open Targets 0.48

Neoplasms

0.53Moderately supported

Clinical evidence dominant · Open Targets 0.40

Lymphoma

0.46Limited support

Clinical evidence dominant · Open Targets 0.37

Precursor Cell Lymphoblastic Leukemia-Lymphoma

0.23Preliminary

Literature evidence dominant · Open Targets 0.13

Leukemia

0.20Preliminary

Literature evidence dominant · Open Targets 0.12

View evidence synthesis (5)

Leukemia, Myeloid, AcuteModerately supported

0.62

agreement 0.47–0.78

Clinical79%Literature21%

Open Targets aggregate 0.48 · 2 independent evidence families

NeoplasmsModerately supported

0.53

agreement 0.37–0.68

Clinical78%Literature22%

Open Targets aggregate 0.40 · 2 independent evidence families

LymphomaLimited support

0.46

agreement 0.30–0.61

Clinical99%Literature1%

Open Targets aggregate 0.37 · 2 independent evidence families

Precursor Cell Lymphoblastic Leukemia-LymphomaPreliminary

0.23

agreement 0.08–0.39

Literature54%Clinical46%

Open Targets aggregate 0.13 · 2 independent evidence families

LeukemiaPreliminary

0.20

agreement 0.05–0.36

Literature57%Clinical43%

Open Targets aggregate 0.12 · 2 independent evidence families

The evidence agreement range shows how closely the independent evidence families agree — it is not a statistical confidence interval, and nothing here is fitted to outcome data. Derived from Open Targets evidence types under Forefront weighting; the per-type scores above show the calculation.

Show all associations

Leukemia, Myeloid, Acute0.48

Neoplasms0.40

Lymphoma0.37

Neurodegenerative Diseases0.24

Precursor Cell Lymphoblastic Leukemia-Lymphoma0.13

Myelodysplastic syndrome0.12

Leukemia0.12

Drug development

5 compounds recorded · 1 approved · 4 in clinical development

Open Targets' development universe — every compound recorded against the target at any stage, not all approved medicines.

View all recorded compounds (5)

FLOTETUZUMABPhase 2

TAGRAXOFUSPApproval

CSL-360Phase 1

TALACOTUZUMABPhase 2 3

PIVEKIMAB SUNIRINEPhase 2 3

Open Targets known-drugs universe. Drug name and highest clinical stage only — the disease relationship is NOT read from this slice (it carries trial-context noise); approved indications come from the canonical graph above.

Tractability

Small molecules — Emerging

Feasibility evidence (structure with ligand) — no clinical-stage drug of this modality recorded.

Antibodies — Strong

Advanced Clinical and UniProt loc high conf support this modality.

Protein degraders — Emerging

Feasibility evidence (uniprot ubiquitination) — no clinical-stage drug of this modality recorded.

Other modalities — Strong

Approved Drug support this modality.

View underlying tractability evidence (7)

SM · Structure with LigandAB · Advanced ClinicalAB · UniProt loc high confAB · GO CC high confAB · UniProt SigP or TMHMMPR · UniProt UbiquitinationOC · Approved Drug

Raw Open Targets tractability assessment buckets, by modality.